A5071202239- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Cutaneous lymphoproliferative disorders research
- Genomics and Rare Diseases
- Molecular Biology Techniques and Applications
- Immune Cell Function and Interaction
- Bone and Joint Diseases
- Glioma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- CNS Lymphoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Sarcoma Diagnosis and Treatment
- Glycosylation and Glycoproteins Research
- Hemoglobinopathies and Related Disorders
- Breast Cancer Treatment Studies
- Biosimilars and Bioanalytical Methods
- Gene expression and cancer classification
Memorial Sloan Kettering Cancer Center
2021-2025
Kettering University
2022
University of Colorado Anschutz Medical Campus
2018-2021
University of Colorado System
2020
University of Colorado Denver
2018-2019
University of Pittsburgh Medical Center
2018
Stanford University
2005-2016
Cedars-Sinai Medical Center
2016
New York Hospital Queens
2011-2012
Columbia University Irving Medical Center
2011-2012
Key Points Responses and survival with venetoclax for “real-world” AML patients were promising but inferior to those treated in a clinical trial. Compared induction, response rates are as high would be predicted had lower than expected early death rate.
Abstract Background The use of next‐generation sequencing for fusion identification is being increasingly applied and aids our understanding tumor biology. Some fusions are responsive to approved targeted agents, while others have future potential therapeutic targeting. Although some pediatric central nervous system tumors may be cured with surgery alone, many require adjuvant therapy associated acute long‐term toxicities. Identification targetable can shift the treatment paradigm toward...
Abstract Genomic profiling of hematologic malignancies has augmented our understanding variants that contribute to disease pathogenesis and supported development prognostic models inform management in the clinic. Tumor only sequencing assays are limited their ability identify definitive somatic variants, which can lead ambiguity clinical reporting patient management. Here, we describe MSK-IMPACT Heme cohort, a comprehensive data set alterations from paired tumor normal DNA using...
OncoKB, Memorial Sloan Kettering Cancer Center’s (MSK) precision oncology knowledge base, contains evidence-based information about the oncogenic effect and therapeutic implications of somatic alterations in cancer. OncoKB currently includes annotation for >8000 900 cancer-associated genes is only cancer variant database partially recognized by US-FDA. supports interpretation cBioPortal Genomics, used to annotate >17,000 MSK patient sequencing reports annually publicly...
The RAG1 and RAG2 proteins catalyze V(D)J recombination are essential for generation of the diverse repertoire antigen receptor genes effective immune responses. is composed a "core" domain that required reaction C-terminal nonessential or "non-core" region. Recent evidence has emerged arguing non-core region plays critical regulatory role in reaction, mutations this have been identified patients with immunodeficiencies. Here we present first structural data protein, using NMR spectroscopy...
Objectives: Pure erythroid leukemia (PEL) is an extremely rare entity that may, even more rarely, evolve from a preexisting chronic myeloid neoplasm (CMN); there minimal literature regarding this latter phenomenon. Methods: We describe 14 patients with PEL represented progression myelodysplastic syndrome (MDS, n = 8) or myeloproliferative (MPN, 6), three of which manifested as erythroblastic sarcoma (EBS), entity. These had highly complex karyotype prominent clonal evolution and very...
DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found acute myeloid leukemia
Abstract The basis for acquired resistance to JAK inhibition in patients with JAK2-driven hematologic malignancies is not well understood. We report a patient myeloproliferative neoplasm (MPN) BCR activator of RhoGEF and GTPase (BCR)–JAK2 fusion initial response ruxolitinib who rapidly developed B-lymphoid blast transformation. analyzed pre-ruxolitinib transformation samples using genome sequencing, DNA mate-pair sequencing (MPseq), RNA (RNA-seq), chromosomal microarray characterize possible...
Comprehensive genomic sequencing is becoming a critical component in the assessment of hematologic malignancies, with broad implications for patients’ management. In this context, unequivocally discriminating somatic from germline events challenging but greatly facilitated by matched analysis tumor:normal pairs samples. contrast to solid tumors, malignancies conventional sources normal control material (peripheral blood, buccal swabs, saliva) could be highly involved neoplastic process,...
Hairy cell leukaemia (HCL) is a rare type of B-cell non-Hodgkin lymphoma (B-NHL), which not known to be associated with any characteristic recurrent karyotypic abnormality. A recent study that used massively parallel whole exome sequencing identified an activating V600E mutation in BRAF, appeared specific for HCL. Here, we confirm the specificity BRAF HCL among low and intermediate grade B-NHL describe real-time polymerase chain reaction method detecting this cases tumour burden. The does...
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an uncommon non-Hodgkins primary cutaneous that typically presents as subcutaneous nodules on the extremities or trunk. Here, we report unusual case of systemic panniculitic with predominantly mesenteric extra-cutaneous involvement and aggressive clinical course histopathologic immunophenotypic features mimic SPTCL. This serves to expand body literature regarding SPTCL-like disorders prominent involvement.
Dasatinib, a second-generation tyrosine kinase inhibitor with activity against BCR-ABL1 and other Src family kinases, is approved as first-line treatment option for Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in the phase. Recently, lymphadenopathy morphologic features of reactive follicular hyperplasia was described cohort patients CML on long-term dasatinib therapy. However, complete immunophenotypic this previously underappreciated adverse effect have not been...
To the Editor: In cutaneous T-cell lymphomas/lymphoproliferative disorders (CTLs), T cells are usually monoclonal, whereas in reactive infiltrates, they most often polyclonal.1Pulitzer M. Cutaneous lymphoma.Clin Lab Med. 2017; 37: 527-546https://doi.org/10.1016/j.cll.2017.06.006Abstract Full Text PDF PubMed Scopus (56) Google Scholar Analysis of receptor (TCR) using multiplex polymerase chain reaction (PCR) is standard for clonality testing; however, this method time-consuming, expensive,...
Venetoclax with azacitidine (ven/aza) is a lower-intensity therapeutic regimen that has been shown to improve outcomes in elderly patients acute myeloid leukemia (AML). Measurable residual disease (MRD) using flow cytometry valuable tool for the prediction of relapse AML conventional therapies and ven/aza; however, prognostic value broad-scale molecular MRD after ven/aza treatment less clear. We aimed determine utility retrospective assessment multi-gene by droplet digital PCR (ddPCR). found...
Leveraging endogenous tumor-resident T-cells for immunotherapy using bispecific antibodies (BsAb) targeting CD20 and CD3 has emerged as a promising therapeutic strategy patients with B-cell non-Hodgkin lymphomas. However, features associated treatment response or resistance are unknown. To this end, we analyzed data from treated epcoritamab-containing regimens in the EPCORE NHL-2 trial (NCT04663347). We observed downregulation of expression on B-cells following initiation both progressing...